EuBiologics On COVID-19 Vaccine And Fulfilling Public Health Mission
Low-Income Countries Targeted
EuBiologics CEO Yeong Ok Baik sat down with Scrip at CPhI Korea to talk about why he wants to develop vaccines for global public health needs and what plans are in store for its late-stage recombinant protein candidate for COVID-19.
You may also be interested in...
Following positive interim Phase I/II results, expectations are rising for SK Bioscience’s recombinant COVID-19 vaccine as it becomes the first Korea-developed candidate to progress to Phase III.
South Korea is stepping on the gas to develop its own mRNA COVID-19 vaccine and eventually next generation mRNA platform technology for use in other diseases, to meet its goal of becoming a global vaccine hub.
Financing for Korean bioventures and pharma firms remained strong this year amid ample liquidity and strong investor sentiment in the sector. SK Bioscience's IPO was the top fundraiser in 2021, followed by HK inno.N’s offering, while GI Innovation raised the most money from venture capital sources.